Transitioning to Biosimilars: Considerations for Providers and Payers

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asked Brogan about the key opportunities provided by biosimilars for inflammatory conditions, specifically seeking her insights on opportunities around adalimumab (Humira) biosimilar access and use for providers and payers.

Brogan responded that biosimilars provide cost savings opportunities through competition, which could free up health care dollars for other needed treatments. The VOLTAIRE trials with adalimumab biosimilar BI 695501 (adalimumab-adbm, Cyltezo; Boehringer Ingelheim) included Crohn disease patients, providing indication-specific data to reassure providers. From the payer perspective, adalimumab biosimilar competition allows price negotiations and access to discounts off the originator price. Payers will need to adapt formularies and provide education to ensure successful adoption.

Haumschild agreed cost savings would be beneficial, but noted provider concerns around immunogenicity, switching limits, and product differences that require thoughtful education so that patients understand without getting overwhelmed.

Video synopsis is AI-generated and reviewed by editorial staff.